{
    "clinical_study": {
        "@rank": "115861", 
        "arm_group": {
            "arm_group_label": "Elderly patients", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "FK949E will be administered to elderly bipolar disorder patients with major depressive\n      episode for 52 weeks.  Its safety, efficacy, and plasma concentration change will be\n      evaluated in an open-label manner."
        }, 
        "brief_title": "Long-term Study of FK949E in Elderly Bipolar Disorder Patients", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Bipolar Disorder", 
            "Elderly"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Bipolar Disorder", 
                "Depression", 
                "Depressive Disorder"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of bipolar I or II disorder as specified in the DSM-IV-TR, with a major\n             depressive episode\n\n          -  Able to participate in the study with understanding of and compliance with subject\n             requirements during the study in the investigator's or subinvestigator's opinion\n\n          -  Male subjects must agree to take appropriate contraceptive measures with condoms\n             during the study period.\n\n          -  Female subjects must be confirmed to have no childbearing potential during the study\n             period\n\n        Exclusion Criteria:\n\n          -  Concurrent or previous history of DSM-IV-TR Axis I disorders, except bipolar\n             disorder, within the last 6 months before informed consent\n\n          -  Concurrence of DSM-IV-TR Axis II disorder that is considered to greatly affect\n             patient's current mental status.\n\n          -  The Young Mania Rating Scale (YMRS) total score of 13 points or more.\n\n          -  Nine or more mood episodes within the last 12 months before informed consent.\n\n          -  Lack of response to at least 6-week treatment with at least 2 antidepressants for the\n             current major depressive episode in the investigator's or subinvestigator's opinion\n\n          -  The current major depressive episode persisting for more than 12 months or less than\n             4 weeks before informed consent.\n\n          -  History of substance dependence (other than caffeine and nicotine) or alcohol abuse\n             or dependence.\n\n          -  Treatment with a depot antipsychotic within the last 49 days before primary\n             registration.\n\n          -  Unable to suspend antipsychotics or antidepressants after primary registration\n\n          -  Treatment with two or more of mood stabilizers (lithium carbonate and/or sodium\n             valproate) and lamotrigine, if these drugs, except one of either drug, cannot be\n             suspended after primary registration.\n\n          -  Unable to suspend antiepileptics (except lamotrigine and sodium valproate),\n             antianxiety agents, hypnotics, sedatives, psychostimulants, antiparkinsonian agents,\n             cerebral ameliorators, antidementia agents, or anorectics, except those specified as\n             conditionally-allowed concomitant drugs, from 7 days before primary registration\n\n          -  Electroconvulsive therapy within the last 83 days before primary registration.\n\n          -  A possible need of psychotherapy during the study period (unless the therapy has been\n             commenced at least 83 days before primary registration).\n\n          -  The Hamilton Depression Rating Scale (HAM-D17) suicide score of 3 points or more,\n             history of suicide attempt within the last 6 months before informed consent, or the\n             risk of suicide in the investigator's or subinvestigator's opinion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01737268", 
            "org_study_id": "6949-CL-0022"
        }, 
        "intervention": {
            "arm_group_label": "Elderly patients", 
            "description": "oral", 
            "intervention_name": "FK949E", 
            "intervention_type": "Drug", 
            "other_name": "quetiapine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "FK949E", 
            "Major depressive episode", 
            "patients"
        ], 
        "lastchanged_date": "November 27, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Hokkaido", 
                    "country": "Japan"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Long-term Study of FK949E in Elderly Patients -Long-term Study in Elderly Bipolar Disorder Patients With Major Depressive Episodes-", 
        "overall_contact": {
            "email": "clintrialtrials_info@jp.astellas.com", 
            "last_name": "Clinical Development Administration Dept."
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Montgomery-Asberg Depression Rating Scale (MADRS) total score", 
            "safety_issue": "No", 
            "time_frame": "Change from Baseline to 52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01737268"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "HAM-D (Hamilton Depression Scale)", 
                "measure": "HAM-D17", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline to 52 weeks"
            }, 
            {
                "measure": "Clinical Global Impression-Bipolar-Severity (CGI-BP-S)", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline to 52 weeks"
            }, 
            {
                "measure": "Safety assessed by the incidence of adverse events, vital signs, 12-lead ECGs and Labo-tests", 
                "safety_issue": "No", 
                "time_frame": "for 52 weeks"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}